Oludare Odumosu

Member Since 2021

Oludare Odumosu

Global Managing Director and CEO

Zelira Therapuetics


Oludare ("Dare") Odumosu, PhD, is the CEO of a global cannabis formulation and research company Zelira Therapeutics, which recently made history with the world’s first successful Phase 1/2a clinical trials for a cannabis-based insomnia medicine, and just announced its second world-first. As a publicly traded company on the Australian market (ASX: ZLD) (OTCQB: ZLDAF), Zelira and Dr. Odumosu made news for undergoing a major leadership and culture shift to consolidate its corporate operations in the United States, under Dr. Odumosu's leadership as CEO, while simultaneously maintaining its public trading and government-supported research efforts in Australia. He currently has several CBD and THC formulations in the market focused on PTSD, Autism, Parkinson’s and more. With his leadership and formulations, Dr. Odumosu’s Zelira is also making a claim on the huge CBD market, and recently launched SprinJene CBD, an oral care line, this is the first of many more CBD health-and-wellness products to be launched in the US as early as this year. As a self-described “Nigerian by birth, American by choice,” Dr. Odomusu also represents the new generation of young, multicultural leaders in cannabis, to date at age 37, he is one of the youngest black CEOs of a publicly traded global company.


September 30th, 2021

15 Effective Ways Business Leaders Can Inspire Employees to Constantly Learn and Grow

Encouraging growth and development sets up the employee and the company for future success.

September 10th, 2021

Nine Ways These Entrepreneurs Are Leveraging Tech to Succeed in Their Niche

By using tech intentionally, you can improve your business and the niche in which it operates.


Zelira Therapuetics

Zelira Therapeutics Ltd (formerly Zelda Therapeutics) is a leading global therapeutic medicinal cannabis company with access to the world’s largest and fastest growing cannabis markets. www.zeliratx.com


  • Medicinal cannabis
  • Clinical Trials
  • Breast Cancer